Kiniksa is no longer a launch-story biotech. It is a profitable single-product franchise that still has most of its labeled population untreated, and it is using that cash to build a wholly owned monthly successor before the licensed weekly product loses orphan protection. The second-quarter print raised full-year ARCALYST sales guidance into a band near $1 billion. That raise is the commercial proof. The investment debate is whether the market is paying for a durable interleukin-one category owner or for a fifty-fifty licensed trap whose exclusivity clock is already visible.
The mechanism is not a one-time stocking bounce. Chief operating officer Ross Moat described the largest quarterly net-revenue step-up since launch, driven by first-time writers, repeat writers, a new direct-to-consumer campaign called Heart's Home, and American College of Cardiology guidance that places ARCALYST after anti-inflammatories and colchicine and before steroids. Roughly 21% of the 14000 multiple-recurrence patients sit on therapy. That still leaves most of the concentrated pool, plus a larger first-recurrence pool that already supplies about 20% of new scripts. Collaboration profit grew faster than sales, which is the operating-leverage tell after Regeneron takes half.
Cash at mid-year sat near $526 million with no debt, and the quarter generated about $58 million of net cash. Research spending more than doubled as KPL-387 moved from dose-focusing data into PASTORALE, the pivotal randomized-withdrawal study. The owned monthly antibody is the attempt to keep the franchise after orphan exclusivity on the weekly trap runs off in March 2028. Does penetration keep grinding, and does PASTORALE stay on the RHAPSODY template, or does the multiple already assume both?